GeneLux Therapeutics, Inc. (NASDAQ: GNLX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies using its proprietary oncolytic virus platform. The company’s lead candidate, GL-ONC1 (Olvi-Vec), is an engineered vaccinia virus designed to selectively infect and destroy cancer cells while stimulating systemic anti-tumor immune responses. Through a combination of preclinical research and ongoing clinical trials, GeneLux aims to advance its platform across a range of solid tumors and hematologic malignancies, with an emphasis on improving patient outcomes in difficult-to-treat cancers.
Originally founded as Genelux (NASDAQ:GNLX) and rebranded in 2022 to GeneLux Therapeutics, the company has established a diversified pipeline that includes monotherapy and combination studies in ovarian cancer, malignant pleural mesothelioma and urothelial carcinoma. GeneLux has built internal manufacturing capabilities compliant with Good Manufacturing Practice (GMP) standards to support scale-up for late-stage clinical trials. Strategic collaborations with academic research centers and contract development organizations bolster the company’s translational research and regulatory filing efforts.
Headquartered in New York with research and process development laboratories in Oklahoma City, GeneLux maintains a global footprint through investigator-initiated clinical studies in Europe and Asia. By partnering with leading oncology centers, the company seeks to generate robust clinical data and explore novel combination strategies involving immune checkpoint inhibitors and other emerging therapies. This geographic and strategic diversity reflects GeneLux’s commitment to addressing unmet medical needs across multiple regions and patient populations.
Led by President and Chief Executive Officer Jeffrey Shore, who brings extensive experience in virology and immuno-oncology, GeneLux’s management team combines deep expertise in drug development, regulatory affairs and commercial strategy. The board of directors and scientific advisory board include seasoned professionals with backgrounds in clinical operations, translational research and corporate governance. Together, they guide GeneLux’s mission to innovate in oncolytic virus therapy and advance new treatment options for patients battling refractory cancers.
